PM February 2026 Options Begin Trading

Philip Morris International (PM) options trade ideas: a $160 put is bid $3.60 with the stock at $162.62, implying an effective purchase basis of $156.40 and a 2.25% return (18.66% annualized) if the put expires worthless; the odds of that outcome are currently estimated at 58%. A $165 covered call is bid $3.00 and would produce a 3.31% total return to $165 at February 2026 expiration (1.84% boost, 15.30% annualized) with a 54% chance of expiring worthless. Implied volatilities are 30% (put) and 27% (call), with trailing 12-month volatility calculated at 27%.

Analysis

Market structure: Short-dated option sellers and yield-seeking income funds are the immediate winners — selling the Feb‑2026 PM 160 put nets an effective entry at $156.40 (≈3.7% below spot) while covered‑call sellers can pocket a 3.31% capped upside to $165. That bid/ask suggests elevated demand for downside protection (put IV 30% vs call IV 27%), implying asymmetric investor concern about left‑tail moves even though trailing vol is 27%.

Risk assessment: Tail risks are regulatory action (flavor bans, FDA rulings), currency shocks across EM markets and litigation — low probability but capable of 15–30% downside in a single catalyst window. Near term (days–weeks) focus on IV spikes around earnings/FDA; medium term (months) watch FX and RRP adoption rates; long term (years) execution on reduced‑risk products and buybacks will determine valuation multiple.

Trade implications: Primary tactical plays are cash‑secured put sells (collect ~2–3% premium) or covered calls to boost yield, but size and protection matter — prefer capped credit spreads (e.g., sell 160/ buy 150 put) to limit a catastrophic assignment. For relative exposure, favor PM vs U.S. tobacco (Altria MO) given PM’s international pricing power and RRP mix; use small directional put spreads as tail hedges ahead of known catalysts.

Contrarian angles: The market underprices regulatory/FX tail risk — annualized YieldBoosts of 15–19% overstate realized return because they ignore assignment timing, dividend capture and tax. Historical parallels (tobacco post‑regulatory scares) show deep, short‑lived drawdowns followed by multi‑quarter recoveries; therefore, option sellers should cap downside with protection and buyers should size for event risk rather than pure carry.

Key Decisions for Investors

• Sell cash‑secured PM Feb‑2026 160 puts sized to 1–2% of portfolio capital (target effective entry $156.40). If unwilling to accept assignment, convert into a 160/150 put credit spread to cap max loss at ~$10 minus premium received; close or roll if PM <150 or IV >45%.
• If already long PM, sell Feb‑2026 165 covered calls for ~3.3% upside + premium (size 2–4% of portfolio). If PM rises above 170 pre‑earnings, close to avoid forced assignment; if assigned, accept sale to lock 3.3% plus dividends.
• Establish a defensive tail hedge: buy 155/145 put spreads expiring through next major catalyst (earnings or FDA decision) sized 0.5–1% of portfolio to limit downside between 155–145 while keeping cost low.
• Relative trade (6–12 months): go long PM and short MO on equal dollar exposure (1–3% net directional exposure). Rationale: PM’s international RRP momentum and FX diversification should outperform domestic Altria if macro stabilizes; unwind if spread narrows >10% or PM reports negative RRP guidance.